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BACKGROUND: NT-proBNP (N-terminal pro-B-type natriuretic peptide) improves the discriminatory ability of risk-prediction 
models in type 2 diabetes mellitus (T2DM) but is not yet used in clinical practice. We assessed the discriminatory strength of 
NT-proBNP by itself for death and cardiovascular events in high-risk patients with T2DM.
METHODS AND RESULTS: Cox proportional hazards were used to create a base model formed by 20 variables. The discriminatory 
ability of the base model was compared with that of NT-proBNP alone and with NT-proBNP added, using C-statistics. We stud-
ied 5509 patients (with complete data) of 8561 patients with T2DM and cardiovascular and/or chronic kidney disease who were 
enrolled in the ALTITUDE (Aliskiren in Type 2 Diabetes Using Cardiorenal Endpoints) trial. During a median 2.6-year follow-up 
period, 469 patients died and 768 had a cardiovascular composite outcome (cardiovascular death, resuscitated cardiac arrest, 
nonfatal myocardial infarction, stroke, or heart failure hospitalization). NT-proBNP alone was as discriminatory as the base model 
for predicting death (C-statistic, 0.745 versus 0.744, P=0.95) and the cardiovascular composite outcome (C-statistic, 0.723 
versus 0.731, P=0.37). When NT-proBNP was added, it increased the predictive ability of the base model for death (C-statistic, 
0.779 versus 0.744, P<0.001) and for cardiovascular composite outcome (C-statistic, 0.763 versus 0.731, P<0.001).
CONCLUSIONS: In high-risk patients with T2DM, NT-proBNP by itself demonstrated discriminatory ability similar to a multivari-
able model in predicting both death and cardiovascular events and should be considered for risk stratification.
REGISTRATION: URL: https://www.clini caltr ials.gov; Unique identifier: NCT00549757.
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proportional hazards models
Individuals with type 2 diabetes mellitus (T2DM) have a higher risk of dying than people of comparable age and sex without diabetes mellitus. Cardiovascular 
disease (CVD) affects approximately one-third of all 
people with T2DM and accounts for half of all deaths 
in this population despite major advances in the treat-
ment of the disease.1,2
Comorbidities associated with T2DM are important 
contributors to this increased risk.3 Multivariable pro-
portional hazards models to predict the risk of death 
and cardiovascular events incorporate factors known 
to influence survival such as demographic variables, 
cardiovascular conditions, and laboratory markers of 
disease severity and organ involvement.4 Meanwhile, 
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some existing risk-prediction scores based on the use 
of these traditional variables were considered inaccu-
rate in patients with T2DM.5
BNPs (B-type natriuretic peptides), biomarkers of 
myocardial stress, are well-established predictors of 
outcomes in heart failure (HF).6,7 They have also been 
shown to incrementally improve predictive discrimina-
tion of death and cardiovascular events when incorpo-
rated into multivariable models in the general population 
of individuals with T2DM,8–11 especially in the presence 
of HF,12,13 chronic kidney disease (CKD),14–16 and recent 
acute coronary syndrome.17,18 Despite the evidence, in 
clinical practice, the use of natriuretic peptides is not 
yet consolidated in the risk assessment of patients with 
T2DM.
A recent study quantitating the relative contri-
butions of clinical variables and biomarkers in the 
ELIXA (Evaluation of Lixisenatide in Acute Coronary 
Syndrome) trial found that the BNPs were the most 
important predictors of death and of having a nonfa-
tal cardiovascular event. For death, natriuretic pep-
tides levels alone provided predictive ability that was 
comparable to the use of all other conventional factors 
combined in a multivariable model.17
In this study, we assessed the discriminatory abil-
ity provided by NT-proBNP (N-terminal pro-BNP) 
by itself for the prediction of both death and a car-
diovascular composite outcome (CVCO) compared 
with a multivariable model in patients with T2DM and 
CVD or/and CKD who were enrolled in the ALTITUDE 
(Aliskiren in Type 2 Diabetes Using Cardiorenal Points; 
NCT00549757) trial.19
METHODS 
We performed an analysis of 5509 people (with com-
plete data) of 8561 individuals screened at 838 centers 
in 36 countries and randomly enrolled in the ALTITUDE 
trial.20
Male or female individuals ≥35 years of age were 
included if they used antidiabetic drugs or had doc-
umented fasting plasma glucose ≥126  mg/dL or 
2-hour plasma glucose ≥200  mg/dL; concomitant 
use of angiotensin-converting enzyme inhibitors 
or angiotensin II receptor blockers without any ad-
justments to antihypertensive therapy for at least 
4  weeks before randomization; and at least one of 
the following conditions: persistent macroalbumin-
uria (urine albumin-to-creatinine ratio ≥200  mg/g) 
and estimated glomerular filtration rate ≥30 mL/min 
per 1.73 m2; persistent microalbuminuria (urine albu-
min-to-creatinine ratio ≥20 mg/g) or/and a history of 
CVD (myocardial infarction, stroke, HF, or coronary 
heart disease, and a mean estimated glomerular fil-
tration rate ≥30 mL/min per 1.73 m2). Patients were 
excluded if they had serum potassium >5.0 mmol/L 
directly preceding randomization, type 1 diabetes 
mellitus, unstable serum creatinine (≥20% difference 
between 2 consecutive serum creatinine measure-
ments), New York Heart Association class III or IV HF, 
stroke, acute coronary syndrome, revascularization, 
HF hospitalization in the prior 3  months, history of 
cancer, renal transplant, uncontrolled hypertension, 
treatment with >2 agents blocking the renin–angio-
tensin aldosterone system, or use of potassium-spar-
ing diuretics.20
The study was approved by the ethics committee or 
institutional review board at each participating center, 
and all participants signed informed consent before 
enrollment.19,20
CLINICAL PERSPECTIVE
What Is New?
• In high-risk patients with type 2 diabetes mel-
litus, NT-proBNP (N-terminal pro-B-type natriu-
retic peptide) was the major predictor of death 
and cardiovascular events and, by itself, dem-
onstrated a discriminatory ability similar to a 
model formed by 20 important clinical variables.
• When added to the multivariable model, NT-
proBNP significantly increased the model’s abil-
ity to predict risk.
What Are the Clinical Implications?
• Our findings underscore the ability of NT-
proBNP by itself to be as discriminatory as mul-
tiple variables combined, not as a suggestion to 
replace their use but rather to demonstrate the 
strength of the information encapsulated in this 
biomarker and its potential to improve risk-strat-
ification models in patients with type 2 diabetes 
mellitus and cardiovascular disease, chronic 
kidney disease, or both.
Nonstandard Abbreviations and Acronyms 
CKD chronic kidney disease
CVCO cardiovascular composite outcome
CVD cardiovascular disease
HF heart failure
hs-TnT high-sensitivity cardiac troponin
MI myocardial infarction
NT-proBNP  N-terminal pro-B-type natriuretic 
peptide
T2DM type 2 diabetes mellitus
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Participants were randomized to receive aliskiren or 
placebo.20 The intervention had no effect on the pri-
mary and secondary end points but was associated 
with more adverse drug effects.20
Demographic information and clinical data were re-
corded in an electronic case report form. All data per-
taining to baseline variables including demographics, 
anthropometrics, clinical information, laboratory tests, 
and prior medical history were obtained at the time of 
randomization in the study. All events were reported to 
a centralized and independent adjudication committee 
at Brigham and Women’s Hospital (Boston, MA) that 
classified events according to prespecified definitions 
(Data S1).19,20
The study end points were defined as death from 
any cause and a CVCO (prespecified as a second-
ary cardiovascular end point in the ALTITUDE trial, as 
previously published, and defined as cardiovascular 
death, resuscitated cardiac arrest, nonfatal myocardial 
infarction, nonfatal stroke, or unplanned hospitalization 
for HF).19,20
All laboratory variables were centrally measured.20 
NT-proBNP and hs-TnT (high-sensitivity cardiac tropo-
nin) values <25 pg/mL and 13 ng/L were converted to 
12.5 pg/mL and 6.5 ng/L, respectively (Data S2).
Statistical Analysis
Baseline characteristics shown in Table  1 were se-
lected to create the risk models. We examined all vari-
ables collected in the electronic case report form. The 
most statistically significant or clinically relevant base-
line variables were added to the model. Nonsignificant 
variables were removed (P>0.05) unless considered 
clinically important. The distributions of baseline NT-
proBNP, hs-TnT, and other variables that were found 
to be right-skewed were log-transformed before 
analysis. Continuous variables were included in the 
model unless there was clear evidence of nonlinearity. 
Between-group differences were tested for statistical 
significance with Student t test or Wilcoxon rank sum 
test for continuous variables; the χ2 test was used for 
categorical variables.
Cox proportional hazards modeling was used to 
create the multivariable base risk model, which was 
formed using selected clinical and laboratory variables 
without NT-proBNP. The discriminatory ability of the 
base model was compared with that of NT-proBNP 
alone and with that of the base model after addition of 
NT-pro BNP, using Harrell C-statistics.
The base model was formed by 20 clinical vari-
ables: age (per 10  years), sex, smoking, history of 
coronary heart disease (previous hospitalizations due 
to percutaneous coronary intervention, coronary ar-
tery bypass grafting, angina, or myocardial infarction), 
history of stroke, history of prior HF, history of atrial 
fibrillation, insulin use, systolic blood pressure (per 
10 mmHg), diastolic blood pressure (per 10 mmHg), 
heart rate (per 10  beats/min), left ventricular hyper-
trophy on ECG, Q wave on ECG, any bundle-branch 
block on ECG, log-transformed hs-TnT (per 1 log unit), 
estimated glomerular filtration rate (per 10  mL/min 
per 1.73  m2), log-transformed urine albumin-to-cre-
atinine ratio (per 1 log unit), glycosylated hemoglo-
bin (per 1%), low-density  lipoprotein cholesterol (per 
1 mg/dL), and serum albumin (per 1 mg/dL).
We also performed an additional statistical analy-
sis by dividing the study population into independent 
sets of training (patients randomized from 2007–2008, 
n=1969) and validation (patients randomized from 
2009–2011, n=3540). We tested the base model of 
20 clinical and laboratory variables, NT-proBNP alone, 
and NT-proBNP added to the base model in predicting 
death and the CVCO in the training data set. Then we 
evaluated the performance of these predictive models 
in the validation data set.
A significance level of 0.05 was considered statisti-
cally significant. Analyses were performed using Stata 
14 (StataCorp).
RESULTS
During median follow-up of 2.6  years (interquar-
tile range, 2.0–3.2), 469 patients (8.5%) died and 
768 (13.9%) experienced a CVCO (cardiovascular 
death, 294 [5.3%]; myocardial infarction, 201 [3.6%]; 
HF unplanned hospitalization, 285 [5.2%]; stroke, 
201 [3.6%]; resuscitated cardiac arrest, 21 [0.4%]) 
(Figure  S1). Baseline characteristics of patients, 
classified by end points, death, and cardiovascu-
lar events, are presented in Table 1. In this analysis, 
2763 patients were randomized to placebo and 2746 
were randomized to aliskiren.
Compared with patients who survived, nonsurvi-
vors were older, on average, with higher systolic blood 
pressure and glycosylated hemoglobin but lower lev-
els of hemoglobin and albumin and lower estimated 
glomerular filtration rate, in addition to a higher previ-
ous load of diseases. Considering patients who had 
cardiovascular events, higher low-density lipoprotein 
cholesterol and albuminuria were observed. Baseline 
levels of NT-proBNP were higher in the nonsurvivor 
group and among those who developed cardiovas-
cular events. There was no difference in aliskiren use 
between the groups.
Table 2 shows the composition of the base model, 
with 20 variables for the prediction of death, the uni-
variable model of log-transformed NT-proBNP (log–
NT-proBNP), and the model containing the addition 
of log–NT-proBNP to the model (21 variables). Table 3 
shows the same models for the prediction of CVCO.
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Table 1. Baseline Characteristics of Patients Classified by Outcome Status (N=5509)
Death CVCO
No Yes
P Value
No Yes
P Valuen=5040 n=469 n=4741 n=768
Age, y 64.1±9.8 68.1±9.3 <0.001 64.0±9.8 67.0±9.2 <0.001
Female sex 1569 (31.1) 129 (27.5) 0.1 1466 (30.9) 232 (30.2) 0.69
Race 0.002 0.014
White 2755 (54.7) 267 (56.9) 2565 (54.1) 457 (59.5)
Black 121 (2.4) 12 (2.6) 113 (2.4) 20 (2.6)
Asian 1876 (37.2) 143 (30.5) 1775 (37.4) 244 (31.8)
Native American 1 (0.0) 0 (0.0) 1 (0.0) 0 (0.0)
Pacific Islander 9 (0.2) 2 (0.4) 7 (0.1) 4 (0.5)
Other 278 (5.5) 45 (9.6) 280 (5.9) 43 (5.6)
BMI, kg/m2 29.7±5.9 29.3±6.0 0.09 29.7±5.9 29.9±6.0 0.35
SBP, mm Hg 137.4±16.2 140.4±17.0 <0.001 137.2±16.1 140.9±16.8 <0.001
DBP, mm Hg 74.4±9.7 73.8±10.5 0.2 74.5±9.7 73.8±10.1 0.07
Heart rate, bpm 72.3±12.4 72.6±13.1 0.61 72.5±12.4 71.8±12.8 0.21
Smoking status 0.08 0.08
No smoker 2498 (49.6) 210 (44.8) 2359 (49.8) 349 (45.4)
Former 1822 (36.2) 193 (41.2) 1715 (36.2) 300 (39.1)
Current 720 (14.3) 66 (14.1) 667 (14.1) 119 (15.5)
Hemoglobin, g/dL 13.2±1.7 12.8±1.8 <0.001 13.2±1.7 13.0±1.8 0.004
Serum albumin, mg/dL 4.3±0.4 4.1±0.5 <0.001 4.3±0.4 4.1±0.4 <0.001
HDL-C, mg/dL 46.2±12.7 46.9±13.9 0.25 46.2±12.7 46.6±13.3 0.43
LDL-C, mg/dL 98.4±36.9 100.4±38.1 0.25 97.7±36.6 103.5±39.3 <0.001
Potassium, mEq/L 4.5±0.5 4.5±0.5 0.65 4.5±0.5 4.5±0.5 0.26
HbA1c, % 7.7±1.5 7.9±1.7 0.015 7.7±1.5 7.9±1.7 <0.001
HbA1c, mmol/mol 60.8±16.7 62.8±18.9 0.015 60.6±16.5 63.2±18.7 <0.001
eGFR, mL/min/1.73 m2 58.0±23.0 51.2±20.1 <0.001 58.1±23.0 53.0±20.8 <0.001
eGFR category <0.001 <0.001
<30 111 (2.2) 21 (4.5) 108 (2.3) 24 (3.1)
30 to <45 1431 (28.4) 192 (40.9) 1331 (28.1) 292 (38.0)
45 to <60 1779 (35.3) 152 (32.4) 1682 (35.5) 249 (32.4)
≥60 1719 (34.1) 104 (22.2) 1620 (34.2) 203 (26.4)
UACR geometric mean, mg/g 209.2 (198.1–220.9) 228.1 (188.1–276.5) 0.37 206.4 (195.2–218.3) 239.6 (205.9–278.9) 0.05
UACR, median (IQR) 301.9 (62.8–894.9) 284.6 (53.9–1272.1) 0.31 297.9 (64.5–863.7) 320.9 (52.8–1340.1) 0.015
UACR category 0.59 0.67
<20 708 (14.0) 69 (14.7) 661 (13.9) 116 (15.1)
20 to <200 1245 (24.7) 124 (26.4) 1183 (25.0) 186 (24.2)
≥200 3087 (61.3) 276 (58.8) 2897 (61.1) 466 (60.7)
BB on ECG 480 (9.5) 86 (18.3) <0.001 438 (9.2) 128 (16.7) <0.001
LVH on ECG 340 (6.7) 51 (10.9) <0.001 319 (6.7) 72 (9.4) 0.008
Q wave on ECG 315 (6.3) 53 (11.3) <0.001 296 (6.2) 72 (9.4) 0.001
T2DM diagnosis time, y 0.29 0.16
>5 4124 (81.8) 395 (84.2) 3870 (81.6) 649 (84.5)
1–5 738 (14.6) 63 (13.4) 705 (14.9) 96 (12.5)
<1 178 (3.5) 11 (2.3) 166 (3.5) 23 (3.0)
Insulin use 2912 (57.8) 300 (64.0) 0.009 2712 (57.2) 500 (65.1) 0.001
Statin use 3220 (63.9) 293 (62.5) 0.54 2996 (63.2) 517 (67.3) 0.027
(Continues)
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In prediction of death, the C-statistic of base model 
was 0.744 (95% CI, 0.722–0.767), and the mortality 
rates per 100 person-years were 0.7 (95% CI, 0.4–1.2) 
in the 1st decile and 11.6 (9.9–13.7) in the 10th decile of 
predicted risk (Figure 1). The C-statistic for NT-proBNP 
as a single variable was 0.745 (95% CI, 0.723–0.768; 
P=0.95 versus model), and the mortality rates per 100 
person-years were 0.7 (95% CI, 0.4–1.2) in the 1st 
decile and 11.6 (95% CI, 9.9–13.6) in the 10th decile of 
NT-proBNP (Figure 1).
In prediction of the CVCO, the C-statistic for the 
20-variable model was 0.731 (95% CI, 0.714–0.749), 
and the incidence rates per 100 person-years were 
0.9 (95% CI, 0.5–1.5) in the 1st decile and 19.2 (95% 
CI, 16.8–22.0) in the 10th decile of predicted risk 
(Figure 2). The C-statistic for NT-proBNP alone was 
0.723 (95% CI, 0.704–0.741; P=0.37 versus model), 
and the incidence rates per 100 person-years were 1.3 
(95% CI, 0.8–2.0) in the 1st decile and 19.4 (95% CI, 
16.9–22.1) in the 10th decile of NT-proBNP (Figure 2).
The C-statistic for predicting death in the base 
model (0.744) was improved by adding NT-proBNP 
(0.779, P<0.001 versus model). Similarly, the model 
ability for predicting the CVCO (0.731) was augmented 
by including NT-proBNP in the model (0.763, P<0.001 
versus model). C-statistics for NT-pro BNP alone 
were also improved by use of the base model plus 
NT-proBNP in the prediction of both death (0.745 ver-
sus 0.779, P<0.001) and CVCO (0.723 versus 0.763, 
P<0.001) (Figures 1 and 2).
In the independent training and validation data 
sets, we reached the same conclusion—that NT-pro-
BNP by itself had discriminatory capacity similar to 
the 20-variable clinical model for death and the CVCO 
(Tables S1 through S3).
Sensitivity Analyses
We also performed a sensitivity analysis of 4929 indi-
viduals, excluding 580 patients with a previous history 
of HF. For the prediction of death, once again, NT-
proBNP alone was as good as the model (C-statistic, 
0.726 versus 0.733, P=0.68) and enhanced its abil-
ity when added to the model (0.733 versus 0.768, 
P<0.001).
The same type of sensitivity analysis, excluding in-
dividuals with a previous history of HF, was performed 
for the CVCO, for which NT-proBNP as a single variable 
Death CVCO
No Yes
P Value
No Yes
P Valuen=5040 n=469 n=4741 n=768
β-Blocker use 2453 (48.7) 261 (55.7) 0.004 2258 (47.6) 456 (59.4) <0.001
ACEi use 2143 (43.5) 230 (50.1) 0.006 1989 (43.0) 384 (50.9) <0.001
ARB use 2904 (58.6) 241 (52.4) 0.01 2757 (59.1) 388 (51.5) <0.001
Aliskiren use 2509 (49.8) 237 (50.5) 0.76 2346 (49.5) 400 (52.1) 0.18
History of HF 467 (9.3) 113 (24.1) <0.001 396 (8.4) 184 (24.0) <0.001
History of CABG 578 (11.5) 64 (13.6) 0.16 517 (10.9) 125 (16.3) <0.001
History of PCI 715 (14.2) 72 (15.4) 0.49 659 (13.9) 128 (16.7) 0.042
History of MI 735 (14.6) 108 (23.0) <0.001 662 (14.0) 181 (23.6) <0.001
History of unstable angina 443 (8.8) 60 (12.8) 0.004 394 (8.3) 109 (14.2) <0.001
History of stroke 476 (9.4) 66 (14.1) 0.001 434 (9.2) 108 (14.1) <0.001
History of TIA 211 (4.2) 27 (5.8) 0.11 183 (3.9) 55 (7.2) <0.001
History of amputation 160 (3.2) 34 (7.2) <0.001 158 (3.3) 36 (4.7) 0.06
History of ulcer 147 (2.9) 29 (6.2) <0.001 145 (3.1) 31 (4.0) 0.15
History of AF 381 (7.6) 79 (16.8) <0.001 336 (7.1) 124 (16.1) <0.001
History of atrial flutter 20 (0.4) 3 (0.6) 0.44 19 (0.4) 4 (0.5) 0.63
Pacemaker 114 (2.3) 18 (3.8) 0.033 99 (2.1) 33 (4.3) <0.001
NT-proBNP, pg/mL 389.5±1091.9 1267.9±2611.8 <0.001 357.1±1040.3 1126.1±2286.5 <0.001
hs-TnT, ng/L 18.2±17.9 39.1±124.9 <0.001 17.9±17.7 32.9±98.6 <0.001
Data are shown as mean±SD or n (%) except as noted. ACEi indicates angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II 
receptor blockers; BB, any bundle branch block; BMI, body mass index; CABG, coronary artery bypass grafting; CVCO, cardiovascular composite outcome; 
DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein cholesterol; HF, heart 
failure; hs-TnT, high-sensitivity cardiac troponin; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; LVH, left ventricular hypertrophy; MI, 
myocardial infarction; NT-proBNP, N-terminal pro–B-type natriuretic peptide; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; T2DM, 
type 2 diabetes mellitus; TIA, transient ischemic attack; and UACR, urine albumin-to-creatinine ratio.
Table 1. Continued
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proved to be as discriminatory as the model (0.705 
versus 0.714, P=0.42) and improved its strength when 
added to the model (0.714 versus 0.749, P<0.001).
Regardless of whether the inclusion criteria was 
CVD (n=2237) or CKD (n=3368), the finding of NT-
proBNP being as discriminatory as the model was 
confirmed for predicting death (C-statistic, 0.711 ver-
sus 0.732 [P=0.18] among patients with CVD and 0.743 
versus 0.746 [P=0.82] in those with CKD) and the CVCO 
(0.692 versus 0.711 [P=0.16] among patients with CVD 
and 0.722 versus 0.732 [P=0.40] in those with CKD). 
Only 96 patients (1.7%) met both criteria and were not 
assessed separately.
Sensitivity analyses considering body mass index 
and use of aliskiren are shown in Table S4.
DISCUSSION
Our goal was to evaluate the discriminatory ability of 
NT-proBNP by itself in high-risk patients with T2DM 
and CVD, CKD, or both. We demonstrated that NT-
proBNP alone was able to predict both death and a 
CVCO as accurately as the multivariable model com-
posed of the 20 most significant and relevant clinical 
variables.
Patients with T2DM are at 2 to 4 times greater risk of 
death and cardiovascular events than the general pop-
ulation.2 Validated models, such as the Framingham risk 
score and the UKPDS (United Kingdom Prospective 
Diabetes Study) model, have shown limited ability to 
accurately estimate the cardiovascular risk of individ-
uals with T2DM.4,5 Several studies have proposed im-
provements for risk stratification of patients with T2DM, 
especially those in secondary prevention; suggested 
improvements include the incorporation of clinical in-
formation21 and the addition of cardiac biomarkers.8–18
The importance of BNPs in improving the predic-
tion of cardiovascular events has been well established 
when added to multivariable models. An analysis of 42 
protein biomarkers in the SUMMIT (Surrogate Markers 
for Micro- and Macrovascular Hard Endpoints for 
Innovative Diabetes Tools) consortium involving in-
dividuals with T2DM and without apparent CVD and 
controls, NT-proBNP, followed by hs-TnT and 4 other 
proteins, revealed the ability to increase cardiovascular 
Table 2. Death Prediction Models
Variables
Base Model Base Model+N-TproBNP NT-proBNP by Itself
(20 Variables; C-Statistic, 0.744 
[95% CI, 0.722–0.767])
(21 Variables; C-Statistic, 0.779 
[95% CI, 0.758–0.800])
(1 Variable; C-Statistic, 0.745 [95% 
CI, 0.723–0.768])
HR 95% CI P Value χ2 HR 95% CI P Value χ2 HR 95% CI P Value χ2
Log NT-proBNP, per 1 log unit … … … … 1.62 1.49–1.77 <0.001 118.6 1.94 1.81–2.07 <0.001 383.4
Log hs-TnT, per 1 log unit 1.85 1.63–2.11 <0.001 85.0 1.49 1.29–1.71 <0.001 30.8
Age, per 10 y 1.57 1.39–1.77 <0.001 54.0 1.43 1.26–1.61 <0.001 32.8
Albumin, per 1 mg/dL 0.55 0.43–0.69 <0.001 25.2 0.77 0.6–0.98 0.035 4,.5
History of HF 1.79 1.41–2.28 <0.001 22.7 1.42 1.11–1.81 0.005 7.9
Heart rate, per 10 beats/min 1.10 1.02–1.19 0.015 5.9 1.13 1.05–1.22 0.002 9.5
History of stroke 1.38 1.06–1.80 0.02 5.8 1.43 1.10–1.87 0.008 7.1
HbA1c, per 1% 1.08 1.01–1.14 0.02 5.7 1.09 1.02–1.15 0.007 7.2
Smoking 1.17 1.02–1.35 0.03 4.9 1.17 1.01–1.34 0.03 4.6
LVH on ECG 1.38 1.03–1.86 0.03 4.6 1.17 0.87–1.57 0.30 1.1
Q wave on ECG 1.38 1.02–1.87 0.04 4.3 1.12 0.82–1.53 0.47 0.5
History of AF 1.31 1.00–1.71 0.05 3.8 0.99 0.76–1.29 0.93 0.0
BB on ECG 1.27 1.00–1.62 0.05 3.7 1.07 0.84–1.38 0.57 0.3
Log UACR, per 1 log unit 1.05 0.99–1.11 0.10 2.7 1.03 0.98–1.10 0.24 1.4
SBP, per 10 mmHg 1.05 0.98–1.12 0.15 2.0 1.03 0.97–1.10 0.33 0.9
Female sex 1.16 0.92–1.46 0.22 1.5 0.95 0.75–1.21 0.67 0.2
History of CHD 1.14 0.92–1.42 0.22 1.5 0.97 0.79–1.20 0.79 0.1
LDL-C, 1 mg/dL 1.00 1.00–1.00 0.24 1.4 1.00 1.00–1.01 0.02 5.9
eGFR, per 10 mL/min/1.73 m2 0.97 0.92–1.03 0.34 0.9 1.01 0.96–1.07 0.67 0.2
Insulin use 1.05 0.85–1.28 0.66 0.2 1.13 0.92–1.39 0.26 1.3
DBP, per 10 mm Hg 1.01 0.90–1.13 0.86 0.0 0.98 0.87–1.09 0.70 0.2
AF indicates atrial fibrillation; BB, any bundle-branch block; CHD, coronary heart disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration 
rate; HbA1c, glycated hemoglobin; HF, heart failure; HR, hazard ratio; hs-TnT, high-sensitivity cardiac troponin; LDL-C, low-density lipoprotein cholesterol; LVH, 
left ventricular hypertrophy; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SBP, systolic blood pressure; UACR, urine albumin-to-creatinine ratio.
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outcome prediction.22 Abnormal NT-proBNP and hs-
TnT levels were able to distinguish individuals with 
T2DM at high cardiovascular risk from those at low 
risk in the ARIC (Atherosclerosis Risk in Communities) 
study.8 Another study that evaluated 237 biomarkers 
in 8401 individuals with dysglycemia (59% with previ-
ous CVD) who were enrolled in the ORIGIN (Outcome 
Reduction With Initial Glargine Intervention) trial also 
identified NT-proBNP as the major predictor of car-
diovascular events and death.23 In patients with T2DM 
involved in the ADVANCE (Action in Diabetes and 
Vascular Disease: Preterax and Diamicron Modified 
Release Evaluation) trial, the accuracy of 5-year car-
diovascular risk prediction was increased by 39% with 
NT-proBNP and 46% with hs-TnT in net reclassifica-
tion index when added to the base model.9 Among 
patients with T2DM and microalbuminuria enrolled in 
the Steno-2 (Intensified Multifactorial Intervention in 
Patients With Type 2 Diabetes and Microalbuminuria) 
study, NT-proBNP above the median was associated 
with an increased risk of CVD.14 In the Sun-MACRO 
(Sulodexide Macroalbuminuria) trial, the addition of 
NT-proBNP to a multivariable model improved predic-
tion of cardiovascular end points in patients with T2DM 
and macroalbuminuria.15 Furthermore, in patients with 
T2DM and predialytic CKD and anemia who were eval-
uated in TREAT (Trial to Reduce Cardiovascular Events 
with Aranesp Therapy), the addition of NT-proBNP and 
TnT to the multivariable model was associated with net 
improvement of 17.8% in predicting cardiovascular 
outcome.16 A previous analysis of the ALTITUDE trial 
showed that the response to treatment with aliskiren 
in cardiorenal outcomes was related to baseline levels 
of NT-proBNP.24
Life insurance companies have recognized the pre-
dictive strength of NT-proBNP and use it to assess 
risk of death.25 For death, some previous studies also 
demonstrated the ability of BNPs to improve predic-
tion of the multivariable models in patients with T2DM 
with or without CVD.9–11,15–17 Pfister et al showed that 
NT-proBNP measured at discharge predicts death 
and cardiovascular events in patients with T2DM hos-
pitalized for a broad spectrum of CVDs.26 Studying 
older adults with T2DM, Bruno et al demonstrated that 
Table 3. CVCO Prediction Models
Variables
Base Model Base Model+NT-proBNP NT-proBNP by Itself
(20 Variables; C-Statistic, 0.731 
[95% CI, 0.714–0.749])
(21 Variables; C-Statistic, 0.763 [95% 
CI, 0.746–0.780])
(1 Variable; C-Statistic, 0.723 [95% 
CI, 0.704–0.741])
HR 95% CI P Value χ2 HR 95% CI P Value χ2 HR 95% CI P Value χ2
Log NT-proBNP, per 1 log unit … … … … 1.63 1.52–1.75 <0.001 189.9 1.88 1.78–1.98 <0.001 545.2
Log hs-TnT, per 1 log unit 1.63 1.47–1.81 <0.001 86.5 1.31 1.18–1.47 <0.001 23.3
History of HF 2.11 1.75–2.55 <0.001 60.7 1.69 1.40–2.05 <0.001 29.6
Age, per 10 y 1.32 1.21–1.45 <0.001 34.8 1.21 1.10–1.33 <0.001 15.4
Albumin, per 1 mg/dL 0.58 0.48–0.70 <0.001 34.1 0.80 0.66–0.96 0.02 5.4
LDL-C, 1 mg/dL 1.00 1.00–1.01 <0.001 17.3 1.01 1.00–1.01 <0.001 30.1
History of AF 1.49 1.21–1.85 <0.001 13.5 1.12 0.9–1.38 0.32 1.0
History of stroke 1.46 1.19–1.80 <0.001 13.0 1.51 1.23–1.86 <0.001 15.4
SBP, per 10 mmHg 1.09 1.04–1.15 0.001 11.8 1.07 1.02–1.12 0.01 6.7
HbA1c, per 1% 1.08 1.03–1.14 0.001 11.4 1.10 1.05–1.15 <0.001 15.5
Smoking 1.19 1.07–1.33 0.002 9.9 1.18 1.06–1.31 0.003 8.8
History of CHD 1.29 1.09–1.53 0.003 8.8 1.10 0.93–1.30 0.25 1.3
Female sex 1.26 1.05–1.51 0.01 6.5 1.04 0.87–1.25 0.65 0.2
Log UACR, per 1 log unit 1.06 1.01–1.11 0.012 6.4 1.04 1.00–1.09 0.057 3.6
BB on ECG 1.26 1.04–1.54 0.02 5.4 1.09 0.89–1.33 0.39 0.7
DBP, per 10 mm Hg 0.94 0.86–1.03 0.16 2.0 0.92 0.85–1.01 0.07 3.3
Insulin use 1.12 0.95–1.31 0.18 1.8 1.19 1.01–1.40 0.04 4.2
Q wave on ECG 1.16 0.90–1.49 0.26 1.3 0.93 0.71–1.20 0.57 0.3
Heart rate, per 10 bpm 1.03 0.97–1.10 0.32 1.0 1.06 1.00–1.13 0.06 3.6
LVH on ECG 1.10 0.86–1.42 0.43 0.6 0.94 0.73–1.20 0.60 0.3
eGFR, per 10 mL/min/1.73 m2 0.99 0.95–1.03 0.76 0.1 1.03 0.99–1.08 0.10 2.7
AF indicates atrial fibrillation; BB, any bundle-branch block; CHD, coronary heart disease; CVCO, cardiovascular composite outcome; DBP, diastolic blood 
pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HF, heart failure; HR, hazard ratio; hs-TnT, high-sensitivity cardiac troponin; 
LDL-C, low-density lipoprotein cholesterol; LVH, left ventricular hypertrophy; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SBP, systolic blood 
pressure; and UACR, urine albumin-to-creatinine ratio.
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NT-proBNP, adjusted for covariates, was the strongest 
predictor of cardiovascular mortality.27
Notably, in an analysis of the ELIXA trial, BNPs alone 
were as predictive as the multivariable model for death 
but not for other outcomes in patients with T2DM 
≤180  days after acute coronary syndrome.17 We ex-
panded knowledge about the discriminatory ability of 
NT-proBNP by itself, demonstrating that it was as pre-
dictive as the base model not only for death but also 
for CVCO and in a clinical population of patients with 
T2DM and CVD, CKD, or both. In addition, we showed 
that these results were maintained even in sensitivity 
analyses, excluding patients with a history of HF or 
considering the 2 main inclusion criteria of the study, 
CVD or CKD. Furthermore, NT-proBNP demonstrated 
incremental discriminatory strength when added to the 
model.
This study is a post hoc analysis of a large cohort 
of patients previously enrolled in a neutral clinical trial, 
with the possible limitations of secondary interpreta-
tions. In our data set, there was no information on left 
ventricular function, imaging exams, or social variables 
such as income and educational level, which could 
provide additional contribution to risk prediction.
The mechanisms by which NT-proBNP as a single 
variable has been shown to be such a strong predictor 
of risk of death and cardiovascular events have not yet 
been fully elucidated. It is known that the concentra-
tions of natriuretic peptides may change in relation to 
different variables such as race/ethnicity,28 heart rate,29 
obesity,30 volume overload,24 left ventricular hypertro-
phy,29 HF,6,7,12,13 myocardial ischemia17,18,31 atrial fibril-
lation,32 CKD,14–16 stroke,33 and treatments.7,34 BNPs 
are released from the heart as a counterregulatory re-
sponse to increased stress on the wall, sympathetic 
tone, and vasoconstriction, but they are also associ-
ated with the regulation of numerous physiologic func-
tions that control energy metabolism.35 It is plausible 
that NT-proBNP is sensitive to different influences that 
expand its potential discriminatory capacity when inte-
grating cardiovascular and hemodynamic stress from 
several sources.
Our results underscore the ability of a single bio-
marker to be as discriminatory as multiple variables 
Figure 1. Death prediction models by deciles of predicted risk/deciles of NT-proBNP.
NT-proBNP indicates N-terminal pro-B-type natriuretic peptide; and py, person/years. Base Model: 
formed by high sensitivity cardiac troponin, age, albumin, history of heart failure, heart rate, history of 
stroke, HbA1c, smoking, left ventricular hypertrophy on ECG, Q wave on ECG, history of atrial fibrillation, 
any bundle branch block on ECG, urine albumin-to-creatinine ratio, systolic blood pressure, sex, history 
of coronary heart disease, low density lipoprotein cholesterol, estimated glomerular filtration rate, insulin 
use, and diastolic blood pressure, in decreasing order of χ2; v=variables. Error bars represent 95% CIs.
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combined, not as a suggestion to replace their use but 
to demonstrate the strength of the information encap-
sulated in NT-proBNP and its potential to improve mod-
els of risk stratification in high-risk patients with T2DM.
CONCLUSIONS
In high-risk patients with T2DM, NT-proBNP by itself 
was as discriminatory as the model of 20 traditional 
clinical and laboratory variables in prediction of both 
death and cardiovascular events. This finding does not 
minimize the influence of multiple other factors in the 
prognosis but emphasizes the importance of this bio-
marker as a sensitive integrator of different variables 
and its potential role in risk stratification.
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Data S1. 
 
 
Supplemental Methods: Adjudication of endpoints and definition of outcomes. 
Definitions of death were: cardiovascular (CV) death, including sudden death, death 
during a CV procedure or as a result of procedure-related complications, presumed 
sudden and presumed CV death, or death resulting from a documented CV cause; non-
CV death as an unequivocal and documented non-CV primary cause of death; and 
death unknown when insufficient data were available to make an reasonable 
differentiation of CV or non-CV cause of death. Resuscitated cardiac arrest was defined 
as an experience of sudden death or cardiac arrest successfully resuscitated by 
cardioversion, defibrillation or cardiopulmonary resuscitation with a meaningful recovery 
of consciousness. A myocardial infarction (MI) was defined by the criteria adopted at the 
time of the study by a troponin or creatinine kinase-MB > 2 × upper reference limit (>3 × 
post-percutaneous coronary intervention [PCI] or >5 × post-coronary artery bypass 
grafting [CABG]) and either ischaemic symptoms or new ischemic electrocardiogram 
(ECG) changes. A heart failure (HF) hospitalization was defined as presentation to an 
acute care facility requiring an overnight hospitalization with an unexpected 
exacerbation of HF (one or more symptoms and two or more signs), which required 
treatment with either intravenous diuretics, vasodilators, inotropes, mechanical fluid 
removal, or insertion of an intra-aortic balloon pump for haemodynamic compromise, 
initiation of standing oral diuretics, or intensification of the maintenance diuretic. A 
stroke was defined by a focal neurological deficit of central origin lasting >24 hour, with 
or without imaging confirmation of cerebral infarction or intracerebral hemorrhage. Data 
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on adjudicated time‐to‐event for death and a CV composite outcome were used for 
analyses (19). 
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Data S2. 
 
Supplemental Methods: Laboratory Analysis of Cardiac Biomarkers 
Biological samples were analyzed in central laboratories in the USA and Europe. 
Samples were analyzed in complete patient sets by laboratory personnel blinded to 
treatment allocation and clinical outcomes. NT-proBNP and hs-TnT analyses were 
performed by CRL.Medinet laboratories in Cambridgeshire, UK and Breda, NL. NT-
proBNP was measured in EDTA plasma using an electrochemiluminescence 
immunoassay (proBNP II; Roche Diagnostics GmbH, Penzberg, Germany), with a 
reporting range of 25-35,000 pg/mL. Intra-day and inter-day assay variation coefficients 
were < 2.5% and < 4 %, respectively. NT-proBNP values below 25 pg/mL (lower limit of 
quantification [LLOQ]), observed in 320 (5,8 %) patients, were automatically converted 
to half the minimum value, 12.5 pg/mL. Hs-TnT was measured in EDTA plasma using a 
high sensitivity immunoassay (Troponin T hs; Roche Diagnostics, Roche Diagnostics 
GmbH, Penzberg, Germany) with a reporting range of 5 – 10,000 ng/L. Intra-day and 
inter-day assay variation coefficients were < 3%. Although the LLOQ for the hs-TnT 
used in this analysis has been reported to be 5 ng/L, based on the manufacturer-
determined 99th percentile equal to 14 ng/L and coefficient of variation < 10% at 13 
ng/L, hs-TnT values found below 13 ng/L, observed in 2,167 (39,3%), were 
automatically converted to 6.5 ng/L. Results prior to these conversions of cardiac 
biomarkers values were not available.  
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Table S1. Baseline characteristics in training and validation datasets. 
 
Training dataset 
Randomization year ≤ 2008 
n= 1,969 
Validation dataset 
Randomization year > 2008 
n= 3,540 
Age, y 65.2 ± 9.6 64.0 ± 9.9 
Female sex 548 (27.8%) 1150 (32.5%) 
Race   
   Caucasian 1228 (62.4%) 1794 (50.7%) 
   Black 70 (3.6%) 63 (1.8%) 
   Asian 526 (26.7%) 1493 (42.2%) 
   Native American 0 1 (0.0%) 
   Pacific Islander 8 (0.4%) 3 (0.1%) 
   Other 137 (7.0%) 186 (5.3%) 
BMI, kg/m2 30.3 ± 6.0 29.4 ± 5.8 
SBP, mmHg 138.4 ± 16.0 137.3 ± 16.4 
DBP, mmHg 74.5 ± 9.7 74.3 ± 9.8 
Heart rate (bpm) 71.4 ± 12.5 72.9 ± 12.4 
Smoking status   
   No smoker 867 (44.0%) 1841 (52.0%) 
   Former 821 (41.7%) 1194 (33.7%) 
   Current 281 (14.3%) 505 (14.3%) 
Hemoglobin, g/dL 13.2 ± 1.7 13.1 ± 1.8 
Albumin, mg/L 4.3 ± 0.4 4.3 ± 0.4 
HDLc, mg/L 46.0 ± 12.6 46.4 ± 12.9 
LDLc, mg/L 96.4 ± 35.8 99.7 ± 37.6 
Potassium, mEq/L 4.5 ± 0.5 4.5 ± 0.5 
HbA1c, % 7.6 ± 1.5 7.8 ± 1.6 
HbA1c, mmol/mol 60.0 ± 16.5 61.5 ± 17.1 
eGFR, ml/min/1.73m2 56.1 ± 21.5 58.1 ± 23.5 
eGFR category   
   < 30 41 (2.1%) 91 (2.6%) 
   30 - < 45 603 (30.6%) 1020 (28.8%) 
   45 - < 60 723 (36.7%) 1208 (34.1%) 
   60 or more 602 (30.6%) 1221 (34.5%) 
UACR [IQR] 249.3 [41.5 - 711.6] 333.8 [80.4 - 1013.1] 
UACR category   
   < 20 330 (16.8%) 447 (12.6%) 
   20 - < 200 538 (27.3%) 831 (23.5%) 
   200 or more 1101 (55.9%) 2262 (63.9%) 
BB on ECG 235 (11.9%) 331 (9.4%) 
LVH on ECG 147 (7.5%) 244 (6.9%) 
Q wave on ECG 136 (6.9%) 232 (6.6%) 
Insulin use 1116 (56.7%) 2096 (59.2%) 
Statin use 1353 (68.7%) 2160 (61.0%) 
Betablocker use 1003 (50.9%) 1711 (48.3%) 
History of HF 221 (11.2%) 359 (10.1%) 
History of CABG 289 (14.7%) 353 (10.0%) 
History of PCI 315 (16.0%) 472 (13.3%) 
History of MI 320 (16.3%)  523 (14.8%) 
History of angina 212 (10.8%) 291 (8.2%) 
History of stroke 213 (10.8%) 329 (9.3%) 
History of TIA 116 (5.9%) 122 (3.4%) 
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History of amputation 76 (3.9%) 118 (3.3%) 
History of ulcer 62 (3.1%) 114 (3.2%) 
History of AF 173 (8.8%) 287 (8.1%) 
History of atrial flutter 10 (0.5%) 13 (0.4%) 
History of pace 54 (2.7%) 78 (2.2%) 
ACEi use 881 (44.8%) 1492 (43.7%) 
ARB use 1093 (55.5%) 2052 (59.5%)  
Aliskiren use 994 (50.5%) 1752 (49.5%) 
T2DM diagnosis time, y   
   > 5 y 1654 (84.0%) 2865 (80.9%) 
   1 - 5 y 260 (13.2%) 541 (15.3%) 
   < 1 y 55 (2.8%) 134 (3.8%) 
NT-proBNP, pg/ml 449.9 ± 1232.7 472.3 ± 1359.4 
hs-TnT, ng/L 19.3 ± 19.5 20.4 ± 48.6 
Death 207 (10.5%) 262 (7.4%) 
CV Composite Outcome 330 (16.8%) 438 (12.4%) 
 
CV: cardiovascular; BMI= body mass index, SBP= systolic blood pressure, DBP= 
diastolic blood pressure, HDLc= high-density lipoprotein cholesterol, LDLc= low-density 
lipoprotein cholesterol, HbA1c= glycated haemoglobin, eGFR= estimated glomerular 
filtration rate, UACR= urine albumin-to-creatinine ratio, IQR= interquartile range; ECG: 
electrocardiogram; BB = any bundle branch block, LVH= left ventricular hypertrophy, 
HF= heart failure, CABG= coronary artery bypass grafting, PCI= percutaneous coronary 
intervention MI= myocardial infarction, TIA= transient ischemic attack, AF= atrial 
fibrillation, T2D= type 2 diabetes; y= years; ACEi= angiotensin-converting enzyme 
inhibitors, ARB= angiotensin II receptor blockers, NT-proBNP= N-Terminal pro-B-type 
natriuretic peptide, hs-TnT= high sensitivity cardiac troponin, CV: cardiovascular. 
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Table S2. Prediction of Death in Training and Validation Datasets. 
 
 Base Model (M1) 
(20 variables) 
Base Model + NT-proBNP (M2) 
(21 variables) 
NT-proBNP by Itself (M3) 
(1 variable) 
C-statistics training 
dataset 
n= 1969 
0.742 (0.708 - 0.776) 
 
M1 vs M2, p <0.001 
0.778 (0.746 - 0.810) 
 
M2 vs M3, p <0.001 
0.738 (0.705 - 0.772) 
 
M3 vs M1, p= 0.85 
C-statistics validation 
dataset 
n= 3540 
0.732 (0.702 – 0.762) 
 
M1 vs M2, p= 0.001 
0.760 (0.732 – 0.789) 
 
M2 vs M3, p= 0.073 
0.742 (0.712 – 0.772) 
 
M3 vs M1, p= 0.54 
    
Variables HR 95% CI P X2 HR 95% CI P X2 HR 95% CI P X2 
Log-NT-proBNP, per 1 log 
unit 
     1.68 1.47 1.93 <0.001 55.06 1.96 1.77 2.17 <0.001 165.63 
Log-hs-TnT, per 1 log unit 1.83 1.48 2.26 <0.001 31.47 1.44 1.16 1.80 0,001 10.56      
Age, per 10 years 1.68 1.39 2.02 <0.001 29.16 1.48 1.23 1.79 <0.001 16.56      
History of HF 1.93 1.35 2.75 <0.001 12.96 1.44 1.00 2.07 0.048 3.92      
LVH on ECG 2.01 1.33 3.04 0,001 11.02 1.69 1.12 2.54 0.013 6.15      
History of Stroke 1.58 1.07 2.34 0.021 5.34 1.65 1.12 2.43 0.012 6.35      
BB on ECG 1.46 1.04 2.06 0.031 4.67 1.17 0.82 1.67 0.40 0.72      
Albumin, per 1 mg/dL 0.69 0.46 1.02 0.06 3.46 1.05 0.69 1.59 0.83 0.048      
HbA1c, per 1 % 1.08 0.99 1.19 0.09 2.89 1.09 0.99 1.19 0.09 2.96      
LDLc, per 1 mg/dL 1.00 1.00 1.01 0.10 2.66 1.00 1.00 1.01 0.020 5.43      
Q wave on ECG 1.43 0.91 2.24 0.12 2.37 1.18 0.73 1.88 0.50 0.45      
Log-UACR, per 1 log unit 1.06 0.97 1.16 0.19 1.74 1.05 0.97 1.15 0.25 1.32      
Smoking 1.15 0.93 1.43 0.21 1.61 1.12 0.90 1.39 0.31 1.04      
Heart rate, per 10 bpm 1.07 0.94 1.22 0.29 1.14 1.09 0.96 1.23 0.20 1.66      
Female sex 1.14 0.80 1.63 0.47 0.52 0.93 0.64 1.34 0.68 0.17      
History of CHD 1.11 0.81 1.53 0.52 0.42 0.92 0.67 1.27 0.62 0.24      
SBP, per 10 mm Hg 0.98 0.88 1.08 0.63 0.23 0.95 0.86 1.06 0.37 0.81      
Insulin use 0.96 0.70 1.30 0.78 0.08 1.03 0.75 1.40 0.87 0.03      
History of AF 0.95 0.62 1.45 0.82 0.05 0.76 0.50 1.15 0.19 1.72      
eGFR, per 10 ml/min/1.73 
m2 
1.01 0.93 1.10 0.87 0.03 1.05 0.96 1.14 0.30 1.08      
DBP, per 10 mm Hg 1.01 0.85 1.21 0.92 0.01 0.98 0.83 1.17 0.84 0.04      
 
Log-NT-proBNP= log-transformed N-Terminal pro-B-type natriuretic peptide, Log-hs-
TnT= log-transformed high sensitivity cardiac troponin, HF= heart failure, LVH= left 
ventricular hypertrophy, ECG= electrocardiogram, BB= any bundle branch block, 
HbA1c= glycated haemoglobin, LDLc= low-density lipoprotein cholesterol, Log-UACR= 
log-transformed urine albumin-to-creatinine ratio, CHD= coronary heart disease, SBP= 
systolic blood pressure, AF= atrial fibrillation, eGFR= estimated glomerular filtration 
rate, LDL= low density lipoprotein, eGFR= estimated glomerular filtration rate, DBP= 
diastolic blood pressure, X2= chi square. Hazard ratios were calculated in the training 
dataset. Comparisons between models were made within datasets. 
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Table S3. Prediction of Cardiovascular Composite Outcome in Training and 
Validation Datasets. 
 Base Model (M1) 
(20 variables) 
Base Model + NT-proBNP (M2) 
(21 variables) 
NT-proBNP by Itself (M3) 
(1 variable) 
C-statistics training 
dataset 
n= 1969 
0.732 (0.706 – 0.758) 
 
M1 vs M2, p= 0.001 
0.758 (0.733 – 0.784) 
 
M2 vs M3, p <0.001 
0.717 (0.688 – 0.745) 
 
M3 vs M1, p= 0.27 
C-statistics validation 
dataset 
N= 3540 
0.720 (0.696 – 0.744) 
 
M1 vs M2, p <0.001 
0.752 (0.729 – 0.775) 
 
M2 vs M3, p= 0.001 
0.725 (0.701 – 0.750) 
 
M3 vs M1, p= 0.70 
    
Variables HR 95% CI P X2 HR 95% CI P X2 HR 95% CI P X2 
Log NT-proBNP, per 1 log 
unit 
     1.58 1.41 1.76 <0.001 66.59 1.88 1.73 2.04 <0.001 224,10 
Log hs-TnT, per 1 log unit 1.83 1.55 2.15 <0.001 51.84 1.52 1.28 1.81 <0.001 22.66      
History of HF 2.08 1.56 2.76 <0.001 25.40 1.64 1.24 2.19 0.001 11.63      
Age, per 10 years 1.34 1.15 1.55 <0.001 14.75 1.20 1.04 1.40 0.015 5.95      
History of Stroke 1.63 1.19 2.24 0.002 9.36 1.68 1.23 2.30 0.001 10.63      
Log UACR, per 1 log unit 1.10 1.03 1.18 0.006 7.45 1.09 1.02 1.17 0.015 5.90      
History of AF 1.50 1.09 2.08 0.014 6.05 1.20 0.87 1.66 0.27 1.21      
SBP, per 10 mm Hg 1.10 1.01 1.19 0.020 5.38 1.08 0.99 1.17 0.08 3.06      
LVH on ECG 1.47 1.04 2.08 0.028 4.80 1.24 0.88 1.75 0.22 1.49      
Albumin, per 1 mg/dL 0.71 0.53 0.97 0.030 4.67 1.01 0.73 1.39 0.96 0.00      
LDLc, per 1 mg/dL 1.00 1.00 1.01 0.027 4.88 1.00 1.00 1.01 0.006 7.45      
DBP, per 10 mm Hg 0.86 0.75 0.99 0.035 4.45 0.86 0.74 0.98 0.027 4.93      
History of CHD 1.27 0.98 1.63 0.07 3.35 1.06 0.83 1.36 0.63 0.23      
Female sex 1.29 0.98 1.70 0.07 3.31 1.10 0.83 1.46 0.51 0.44      
BB on ECG 1.26 0.94 1.68 0.12 2.40 1.08 0.81 1.45 0.60 0.28      
HbA1c, per 1 % 1.06 0.98 1.14 0.15 2.10 1.07 0.99 1.15 0.09 2.92      
Heart rate, per 10 bpm 1.06 0.96 1.18 0.22 1.49 1.08 0.97 1.19 0.15 2.04      
Smoking 1.08 0.91 1.28 0.38 0.77 1.06 0.89 1.25 0.54 0.38      
eGFR, per 10 ml/min/1.73 
m2 
1.03 0.97 1.10 0.38 0.76 1.07 1.00 1.14 0.048 3.92      
Insulin use 1.06 0.83 1.35 0.65 0.21 1.12 0.88 1.44 0.35 0.86      
Q wave on ECG 1.07 0.71 1.61 0.74 0.12 0.93 0.61 1.40 0.72 0.12      
 
Log-NT-proBNP= log-transformed N-Terminal pro-B-type natriuretic peptide, Log-hs-
TnT= log-transformed high sensitivity cardiac troponin, HF= heart failure, Log-UACR= 
log-transformed urine albumin-to-creatinine ratio, AF= atrial fibrillation, SBP= systolic 
blood pressure, LVH= left ventricular hypertrophy, ECG= electrocardiogram, LDLc= low-
density lipoprotein cholesterol, DBP= diastolic blood pressure, CHD= coronary heart 
disease, BB= any bundle branch block, HbA1c= glycated haemoglobin, eGFR= 
estimated glomerular filtration rate, eGFR= estimated glomerular filtration rate, X2= chi 
square. Hazard ratios were calculated in the training dataset. Comparisons between 
models were made within datasets. 
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Table S4. Other sensitivity analyses, considering BMI and use of Aliskiren. 
Death Prediction 
 
Cardiovascular Composite Outcome Prediction 
 
Base 
Model 
NT-proBNP 
by Itself 
p 
  
Base 
Model 
NT-proBNP 
by Itself 
p 
 
C-statistics C-statistics 
   
C-statistics C-statistics 
 
BMI 
    
BMI 
   
  < 30 Kg/m2 0.736 0.706 0.89 
 
   < 30 Kg/m2 0.744 0.727 0.22 
   >= 30 Kg/m2 0.746 0.748 0.94 
 
   >= 30 Kg/m2 0.7321 0.719 0.33 
         
Intervention 
    
Intervention 
   
   Aliskiren 0.762 0.755 0.64 
 
   Aliskiren 0.710 0.702 0.58 
   Placebo 0.741 0.735 0.76 
 
   Placebo 0.753 0.742 0.77 
NT-proBNP: N-terminal pro-B-type natriuretic peptide; BMI: body mass index. 
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Figure S1. Number of patients who were screened, who underwent 
randomization, who completed the trail, and who were evaluated in this study. 
 
GCP= good clinical practice, CV= cardiovascular, MI= myocardial infarction, HF hosp= 
heart failure hospitalization.  
 
 
 
 
 
 
 
D
ow
nloaded from
 http://ahajournals.org by on N
ovem
ber 3, 2020
